Stock Analysis

Earnings Miss: VITA 34 AG Missed EPS By 29% And Analysts Are Revising Their Forecasts

VITA 34 AG (ETR:V3V) missed earnings with its latest full-year results, disappointing overly-optimistic forecasters. Results showed a clear earnings miss, with €20m revenue coming in 2.6% lower than what the analystsexpected. Statutory earnings per share (EPS) of €0.37 missed the mark badly, arriving some 29% below what was expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

View our latest analysis for VITA 34

earnings-and-revenue-growth
XTRA:V3V Earnings and Revenue Growth April 3rd 2021

Taking into account the latest results, the current consensus from VITA 34's dual analysts is for revenues of €22.0m in 2021, which would reflect a notable 9.6% increase on its sales over the past 12 months. Per-share earnings are expected to soar 27% to €0.47. In the lead-up to this report, the analysts had been modelling revenues of €22.3m and earnings per share (EPS) of €0.61 in 2021. So there's definitely been a decline in sentiment after the latest results, noting the pretty serious reduction to new EPS forecasts.

It might be a surprise to learn that the consensus price target was broadly unchanged at €21.00, with the analysts clearly implying that the forecast decline in earnings is not expected to have much of an impact on valuation.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the VITA 34's past performance and to peers in the same industry. The analysts are definitely expecting VITA 34's growth to accelerate, with the forecast 9.6% annualised growth to the end of 2021 ranking favourably alongside historical growth of 6.5% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 4.8% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect VITA 34 to grow faster than the wider industry.

Advertisement

The Bottom Line

The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that in mind, we wouldn't be too quick to come to a conclusion on VITA 34. Long-term earnings power is much more important than next year's profits. At least one analyst has provided forecasts out to 2025, which can be seen for free on our platform here.

It is also worth noting that we have found 1 warning sign for VITA 34 that you need to take into consideration.

If you’re looking to trade VITA 34, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

About XTRA:V3V

FamiCord

Engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally.

Moderate growth potential and slightly overvalued.

Advertisement

Updated Narratives

BE
Bejgal
MNSO logo
Bejgal on MINISO Group Holding ·

MINISO's fair value is projected at 26.69 with an anticipated PE ratio shift of 20x

Fair Value:US$26.6928.0% undervalued
44 users have followed this narrative
3 users have commented on this narrative
0 users have liked this narrative
TI
TickerTickle
ORCL logo
TickerTickle on Oracle ·

The Quiet Giant That Became AI’s Power Grid

Fair Value:US$389.8149.5% undervalued
7 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative
AU
AuCA
NLBR logo
AuCA on Nova Ljubljanska Banka d.d ·

Nova Ljubljanska Banka d.d will expect a 11.2% revenue boost driving future growth

Fair Value:€20916.5% undervalued
23 users have followed this narrative
3 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
GOOGL logo
oscargarcia on Alphabet ·

The company that turned a verb into a global necessity and basically runs the modern internet, digital ads, smartphones, maps, and AI.

Fair Value:US$3404.9% undervalued
136 users have followed this narrative
6 users have commented on this narrative
18 users have liked this narrative
TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.4% undervalued
88 users have followed this narrative
11 users have commented on this narrative
18 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$232.7923.6% undervalued
926 users have followed this narrative
6 users have commented on this narrative
22 users have liked this narrative